Development in Biological Technology

SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS

SAN DIEGO, CA AND GENEVA, SWITZERLAND, August 3, 2009 /PRNewswire-FirstCall/ -- Senomyx, Inc. (Nasdaq: SNMX ), a leading company focused on using proprietary technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply indus...

Stemline Therapeutics CEO to Present at IBC's New Frontiers in Cancer Drug Development Conference

NEW YORK, July 30 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company and a leading developer of oncology compounds directed to cancer stem cell targets, today announced that the Company's CEO, Ivan Bergstein M.D. has been invited to present at the New Fron...

Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic

LAUSANNE, Switzerland and MEDFORD, Massachussets, July 30 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and MSM Protein Technologies (MSM), a human ...

Nanotech particles affect brain development in mice

Maternal exposure to nanoparticles of titanium dioxide (TiO2) affects the expression of genes related to the central nervous system in developing mice. Researchers writing in BioMed Central's open access journal Particle and Fibre Toxicology found that mice whose mothers were injected with the n...

PacificGMP and USC to Collaborate on Recombinant Protein Development and Manufacturing for Phase 1 Clinical Trial

SAN DIEGO and LOS ANGELES, July 27 /PRNewswire/ -- PacificGMP, the leader in single-use bioprocessing for development and manufacturing for its client partners, and the University of Southern California (USC) announced today that they have signed an agreement whereby PacificGMP will prov...

PROLOR Biotech Acquires License Option from Yeda for Development of Long-Acting Anti-Obesity Drug

NES-ZIONA, Israel, July 27, /PRNewswire-FirstCall/ -- PROLOR Biotech, Inc. (OTC Bulletin Board: PBTH) formerly Modigene Inc., today announced that it has entered into an evaluation and option agreement with Yeda Research and Development Company Ltd., the technology transfer arm of the ...

OMT announces a breakthrough in the development of a novel human antibody platform

Palo Alto, CA: July 23, 2009 Open Monoclonal Technology, Inc. (OMT), in collaboration with Sangamo BioSciences, Inc. (NASDAQ, SGMO), Sigma-Aldrich Corporation (NASDAQ: SIAL), The Medical College of Wisconsin, and INSERM, today announced the creation of the first targeted knockout rats as detaile...

Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia

SAN DIEGO, June 29 /PRNewswire/ -- Palkion, Inc. announced today that it has initiated preclinical development studies for its orally available anemia therapeutic candidate that modulates the Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PH) enzyme system. In February 2008, Palkion was founded ...

Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals

UPPSALA, Sweden, June 29 /PRNewswire/ -- - Financing Led by SLS Invest Will Fund Gyros to Profitability Gyros AB, the leading provider of automated micro-immunoassays for therapeutic protein development, announces that it has raised SEK 80 million (approximately euro 7.5 million)...

Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates

OSLO, Norway, June 26 /PRNewswire-FirstCall/ -- Clavis Pharma ASA (OSE: CLAVIS) today announced that the Company has raised NOK 129 million (equivalent to USD 20 million) in gross proceeds through a private placement of 10,750,000 new shares, each with a par value of NOK 1.00 at a price of NOK...

Register to Win a Ski Weekend and Make Your Synthesis Easier with EasyMax™: the First Automated Chemistry Development Tool That Requires No Training

EasyMax™ is a small and powerful lab reactor system for the synthesis lab and synthetic organic chemist - heating and cooling without an additional cryostat. For a limited time, METTLER TOLEDO is offering a FREE TRIAL of the first automated chemistry development tool that requires no train...

WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services

SHANGHAI, June 21 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company with operations in China and the United States, today announced that Wei-Min Chang has been appointed Vic...

Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference

AURORA, Ontario, June 19 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: HBP) today announced that Dr. Heman Chao, chief scientific officer at Helix BioPharma Corp., will be presenting a scientific poster describing L-DOS47 analytical method development findings at the 2009 American Ass...

Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours

LAUSANNE, Switzerland and TAMPA, Florida, June 18 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Moffitt Cancer Center (Moffitt), a non-profit Fl...

Berlin Heart Inc. Receives FDA Orphan Product Development Grant

THE WOODLANDS, Texas, June 17 /PRNewswire/ -- Berlin Heart Inc. today announced it has been awarded an Orphan Product Development Grant by the FDA, to support the ongoing Investigational Device Exemption (IDE) study of the EXCOR(R) Pediatric Ventricular Assist Device (VAD). Dr. Christopher Alm...

Strativa's Development Partner, BioAlliance Pharma, Submits Loramyc(R) NDA

WOODCLIFF LAKE, N.J., June 16 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX ), today announced that its development partner, BioAlliance Pharma, has submitted a New Drug Applicat...

Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update

AURORA, Ontario, June 15 /PRNewswire/ -- Helix BioPharma Corp. ("Helix" or the "Company"), (TSX, FSE: "HBP") today announced its product development progress, quarterly highlights and financial results for the third quarter of fiscal 2009, ended April 30, 2009. THIRD QUARTER HIGHLIGHTS AND P...

CoreRx, Inc. Announces Plans for Expansions to Meet the Needs of Growing Pharmaceutical Formulation Development Business

Formulation Development firm CoreRx announces new facility which will add capacity, additional capabilities to growing laboratory in order to meet growing customer demands. Tampa, FL (Vocus) June 15, 2009 -- CoreRx, Inc. has announced plans to purchase a new facility wh...

New MedPredict Report Reveals Top Alzheimer's Experts' Insights on Diagnostics and Treatments in Development Pipeline

SCOTTSDALE, Ariz., June 12 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled "Thought Leader Insight & Analysis: Alzheimer's Disease," designed to provide critical strategic insight ...

PharmaNet Development Group Clinical Research Experts to Present at Global Professional Meetings in June

PRINCETON, N.J., June 10 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, today announced its participation at several international professional meetings d...

Plexus Awarded Development Contract With QIAGEN

NEENAH, Wis., May 28 /PRNewswire-FirstCall/ -- Plexus Corp. (Nasdaq: PLXS ) announced today that it has been selected to develop QIAGEN's next generation automated screening system for the pre-processing of human papillomavirus (HPV) DNA samples. This product provides a highly automated solutio...

AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support

VIENNA, Austria, May 27 /PRNewswire/ -- The atherosclerosis vaccine development program by AFFiRiS AG is receiving financial support from the EU's EUROTRANS-BIO call. The respective project is being carried out in cooperation with German company EMC microcollections GmbH. The aim of atheroscle...

China Sky One Medical, Inc. Signs Agreement with Taiwan Golden Biotechnology Corp. on Development of New Anti-Cancer Drug

HARBIN, China, May 21 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI ), a leading fully integrated pharmaceutical company in the People's Republic of China ("PRC"), today announced that it signed an agreement with Taiwan Go...

Follica Appoints Drug Development and Dermatology Veteran, William D. Ju, as Chief Executive Officer

BOSTON, May 13 /PRNewswire/ -- Follica Inc., a privately held developer of novel therapies for androgenetic alopecia and other hair follicle and skin disorders, today announced that William D. Ju, M.D. has been appointed as president and chief executive officer. Dr. Ju succeeds Daphne Zohar, mana...

Cardium Announces Conference Call and Webcast to Review Recent Developments and Future Plans for the Excellarate(TM) Clinical Development Program

SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM ) today announced that the Company will hold a conference call and webcast to discuss recent developments and future plans for its Excellarate(TM) clinical development program. (Logo: http://www.newscom.com/c...

PTC Therapeutics and Spinal Muscular Atrophy Foundation Announce $8.5 Million Small Molecule Development Collaboration

Project will advance novel platform for treatment of Spinal Muscular Atrophy SOUTH PLAINFIELD, N.J. and NEW YORK, May 12 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) and the Spinal Muscular Atrophy (SMA) Foundation today announced the expansion of their research collaboration in which the SM...

Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy

SAN DIEGO, May 11 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company focused on the treatment of obesity, today announced that Jay Hagan has joined the organization as Senior Vice President of Corporate Development and Strategy. "Jay brin...

Circ Pharma Limited Enters Into Development Agreement for Chrono Tramadol With Elan Corporation Plc

DUBLIN, May 4 /PRNewswire/ -- Circ Pharma Limited ("Circ Pharma") and Elan Corporation plc ("Elan") today announced that they have entered into a Development Agreement to develop a chronotherapeutic formulation of Tramadol for the treatment of moderate to moderately severe pain. The pro...

ALS Therapy Development Institute, the World's Largest Non-Profit Biotech, Appoints Steve Perrin, Ph.D., as Chief Executive Officer

Board of Directors Also Appoints a New President and Adds A New Member CAMBRIDGE, Mass., May 1 /PRNewswire-USNewswire/ -- Steve Perrin, Ph.D., was appointed chief executive officer and Maureen Lister was appointed president of the ALS Therapy Development Institute (ALS TDI) during the annual ...

UMass Boston Opens Venture Development Center to Expand R&D Activity

Facility to Foster Faculty and Student Research, Partnering with Industry Boston (Vocus) May 1, 2009 -- The University of Massachusetts Boston today officially opened a cutting-edge Venture Development Center that will significantly expand the university's research ...

TeleHealth Services Chosen by Baptist Hospital East in Development of New Park Tower

LOUISVILLE, Ky. and RALEIGH, N.C., April 28 /PRNewswire/ -- TeleHealth Services , the nation's leading provider of healthcare on-demand patient and staff education, healthcare televisions and communications solutions, today announced a new contract with Baptist Hospital East, in Louisville, K...

Key Industry-Relevant Development to be Announced at MichBio's 2009 Annual Meeting on May 6

ANN ARBOR, Mich., April 28 /PRNewswire-USNewswire/ -- The following news advisory is being issued by MichBio: What: MichBio Annual Business Meeting - During the meeting an important development for Michigan biosciences will be announced. Who: MichBio, Michigan's trade association f...

DFB Pharmaceuticals Appoints Maxwell Lea to Vice President Business Development and Corporate Finance

FORT WORTH, Texas, April 23 /PRNewswire/ -- DFB Pharmaceuticals, Inc., has announced the promotion of Maxwell A. Lea, III, to Vice President Business Development and Corporate Finance. Mr. Lea was most recently Director of Corporate Development and Finance for the company. "Since joining DFB...

Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver

CAMBRIDGE, Mass., April 23 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported data from its three hepatitis C development programs being pr...

HUYA Bioscience Announces Strategic Alliance With Abbott on Drug and Biomarker Development Candidates From China

Collaboration will leverage HUYA's growing Chinese bioscience network SAN DIEGO, April 21 /PRNewswire/ -- HUYA Bioscience International, a leader in US/China pharmaceutical co-development, today announced an agreement with Abbott to identify and pursue proprietary preclinical and clinical d...

Psylin Neurosciences Commences Development of Compound for Depression

SAN DIEGO, April 20 /PRNewswire/ -- Psylin Neurosciences Inc., a joint venture biotechnology company spun out of Amylin Pharmaceuticals, Inc. and PsychoGenics, Inc. announced today that it has initiated IND-enabling development of a novel compound, PSN0041, for the treatment of depression. ...

NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza

SAN DIEGO, April 15 /PRNewswire/ -- NexBio, Inc. announced today that it has completed the formation of a new Clinical Advisory Board (CAB) to complement its existing group of Senior Advisers. NexBio recently completed a First-In-Man clinical trial of DAS181 (Fludase(R)), an investigational d...

ImmunoVaccine Technologies Collaborates with Defence Research & Development Canada to Strengthen Canada's Ability to Deal with Biological Threats

HALIFAX, April 14 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, has announced the signing of a 3-year research agreement with Defence Research and Development Canada (DRDC). The research collaboration involves the preclinical application of IVT's DepoVax(TM) ...

US Oncology Clinical Development Attends 'Partnerships With CROs'

HOUSTON, April 13 /PRNewswire/ -- US Oncology Clinical Development (USOCD), a full service contract research organization (CRO) will attend the 18th annual conference, Partnerships with CROs, scheduled for April 28-30 in Orlando, Fla. During the course of this meeting, USOCD will meet with key...

NeoStem Completes $11 Million Private Placement Financing to Support Expansion Activities in China, Further Development of NeoStem's VSEL Technology and Advancement of Medical Tourism Initiatives

NEW YORK, April 13 /PRNewswire-FirstCall/ -- NeoStem, Inc. (Amex: NBS ) announced today that it has completed a private placement financing totaling $11 million from three Asia-based investors, including a private equity firm operating in partnership with strategic investors drawn from leading A...